The clinical trial demonstrated that the vaccine was safe and fully attenuated, causing no malaria infections in adults. The vaccine has the potential to achieve unprecedented potency and is designed to align with WHO's goals for malaria elimination.
A single-dose breakthrough: PfSPZ-LARC vaccines offer high-level protection against malaria. By leveraging genetic engineering, the vaccine harnesses weakened parasites that replicate in the liver but halt progression to the blood stage.
A new vaccine has shown to protect mothers from malaria during pregnancy and for up to two transmission seasons without booster doses. The vaccine was well-tolerated and safe for both the mothers and their offspring, with no differences in adverse events compared to placebo.
Researchers have made a breakthrough in producing infectious Plasmodium falciparum sporozoites without the need for mosquitoes, paving the way for more effective malaria vaccines. This achievement accelerates the ability to study the parasite's biology and develop new tools for vaccine development.
Researchers used Plasmodium falciparum 7G8 challenge trials to test the PfNF54-based PfSPZ Vaccine, providing conservative predictions of its efficacy in Africa. The study found that VE over 24 weeks was as good as or better than VE against Pf7G8 CHMI at 24 weeks.
A Sanaria vaccine has demonstrated complete protection against a variant malaria parasite in six subjects, with the dosage being only 20% of its original strength. The results, published in Nature, have significant implications for the prevention of malaria in African populations and travelers to Africa.
Recent studies have demonstrated excellent efficacy of Sanaria's PfSPZ-CVac malaria vaccine, with 77% protection rate in malaria-naive adults. Optimizing immunization timing has increased efficacy to 75%, overcoming negative impacts of blood stage parasites.